Introduction
============

Surgical trauma, burns, and severe infections cause damage to the structure and function of intestinal mucosa, and facilitate intestinal bacterial translocation. This can lead to multiple organ function failure, which is potentially be life-threatening ([@b1-etm-0-0-3799]).

Glutamine (Gln) is a free amino acid that comprises \>50% of the body\'s free amino acid pool ([@b2-etm-0-0-3799]). Gln is a precursor for protein synthesis and is a preferential energy source for immune and mucosal cells. In addition, this amino acid is an important intermediate in many metabolic pathways ([@b3-etm-0-0-3799]). Animal experiments and clinical studies demonstrated that Gln increases the height of intestinal villi, reduces intestinal mucosal permeability and enhances intestinal immune function ([@b4-etm-0-0-3799]). In addition, it prevents bacterial translocation and contributes to maintaining the intestinal mucosal barrier ([@b4-etm-0-0-3799]). The effects of Gln on intestinal inflammatory response and mucosal permeability remain to be elucidated.

In the present study, we conducted a meta-analysis to evaluate the effects of Gln supplementation in patients undergoing abdominal surgery.

Materials and methods
=====================

### Search strategy

A search of the PubMed (<http://www.pubmed.com>), EMBASE (<http://www.embase.com>), Web of Science (<http://apps.webofknowledge.com>), and The Cochrane Library (<http://www.thecochranelibrary.com>) databases was conducted. Specific search strategies were developed for each database, using different combinations and variations of search terms, including 'glutamine', 'Gln', 'surgery', 'surgical', 'inflammatory reaction', 'CRP', 'TNF-α', 'IL-2R', 'IL-6′, 'intestine permeability' 'intestinal barrier', 'lactulose/mannitol', 'DAO', 'D(−)lactic acid', 'endotoxin', and their variants.

### Study selection

Inclusion criteria for the meta-analysis were: i) Study design was a randomized controlled trial, ii) study included patients undergoing abdominal surgery, iii) study patients received a supplementation with Gln peptide (Ala-Gln or Gly-Gln) whereas control patients did not use any supplements, and iv) study outcomes included inflammatory markers \[C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin (IL)-2R, or IL-6\] and markers of intestinal permeability (lactulose/mannitol, diamine oxidase, D(−)lactic acid, and endotoxin). Exclusion criteria for the study were: i) Studies were required to be basic research or animal studies, or systematic reviews, ii) they did not include abdominal surgery patients, iii) data were not complete or original data were not presented, and iv) repeated published reports.

### Data extraction

Data were extracted independently by two investigators according to the pre-specified selection criteria. Discrepancies were resolved by discussion. From each study, information on first author, publication year, sample size, patient age and gender, outcomes, 95% confidence interval (CI), standard deviation, and P-values were extracted. Since differences in study populations and design may have caused variations, a study-quality score was assigned using the methodological quality assessment. This assessment utilized the Jadad quality evaluation scale to rank the quality of the included randomized controlled trials. Thus, studies scored 0 point if they were not randomized controlled trials (these studies were excluded). The studies ranked 1--2 points were low quality studies, whereas studies with 3--5 points were high quality studies. The studies that received 1--5 points were included in this meta-analysis ([Table I](#tI-etm-0-0-3799){ref-type="table"}).

Statistical analysis. Data were analyzed using the statistical software provided by the Cochrane Collaboration (RevMan 5.2; Baltimore, MD, USA) and presented as means ± standard deviations. A classified variable was presented as a relative risk with 95% CI. A summary estimate of continuous data was presented as a weighted mean difference (WMD) with 95% CI. Before calculating the standardized mean effect for the trials, statistical heterogeneity test was evaluated by using the I^2^ statistic (α=0.05), which assessed the appropriateness of pooling individual study results. The I^2^ values of 25, 50 and 75%, respectively, corresponded to low, moderate, and high levels of heterogeneity. The meta-analysis was performed using a fixed-effects model when there was no heterogeneity of results. For heterogeneity, a random-effects model was used. Statistical significance was set at P\<0.05, and two-tailed tests were used.

Results
=======

### Study characteristics

A total of 491 papers using the specified searching strategies were identified. By screening titles, and reading the abstracts and entire papers, 21 randomized controlled trials were selected ([Fig. 1](#f1-etm-0-0-3799){ref-type="fig"}) ([@b5-etm-0-0-3799]--[@b25-etm-0-0-3799]). The included trials were published between August, 1966 and June 2014. Of these trials, 11 randomized controlled trials evaluated the effects of Gln on inflammatory response and 12 randomized controlled trials examined the effects of Gln on markers of intestinal permeability in abdominal surgery patients. Characteristics of randomized controlled trials included in the meta-analysis and the quality assessment of included randomized controlled trials are presented in [Table II](#tII-etm-0-0-3799){ref-type="table"}.

### Inflammatory outcomes

Four studies with 182 subjects presented data on CRP levels. The data were homogeneous (χ^2^=2.51, P=0.47, I^2^=0%; [Fig. 2](#f2-etm-0-0-3799){ref-type="fig"}). Therefore, a fixed-effects model was used for analysis. The CRP levels in Gln-supplemented patients were lower than those in the control patients (WMD=−25.40, 95% CI: −31.94, −18.85; P\<0.00001).

We then identified five studies comprising 286 patients and evaluating the modulation of TNF-α. These studies showed heterogeneity (χ^2^=190.20, P≤0.00001, I^2^=98%; [Fig. 3](#f3-etm-0-0-3799){ref-type="fig"}). Therefore, a random-effects model was utilized. We demonstrated that patients on the Gln supplementation showed a more pronounced decrease of TNF-α levels compared with control patients (WMD=−21.75, 95% CI: −32.67, −10.83; P\<0.0001).

The following tested inflammatory outcome was IL-2R, which was evaluated in two studies comprising 44 patients. The fixed-effects model was used because of acceptable heterogeneity (χ^2^=2.36, P=0.12, I^2^=58%; [Fig. 4](#f4-etm-0-0-3799){ref-type="fig"}). The levels of IL-2R in patients supplemented with Gln were higher than those in control patients (WMD=4.46, 95% CI: 2.85, 6.06; P\<0.00001).

The final inflammatory marker analyzed was IL-6. Four studies (n=198) tested the change of IL-6 levels on Gln supplementation. These studies were heterogeneic (χ^2^=11.45, P=0.010, I^2^=74%; [Fig. 5](#f5-etm-0-0-3799){ref-type="fig"}). Therefore, a random-effects model was used for analysis. IL-6 levels were significantly lower in patients supplemented with Gln (WMD=−10.29, 95% CI: −16.56, −4.02; P=0.001 vs. control patients). Publication bias is shown in [Fig. 6](#f6-etm-0-0-3799){ref-type="fig"}.

### Evaluation of mucous membrane permeability

We analyzed the effects on the ratio of lactulose/mannitol after abdominal surgery. There were six studies comprising 251 patients that reported this ratio. These studies were heterogeneous (χ^2^=27.86, P\<0.0001, I^2^=82%; [Fig. 7](#f7-etm-0-0-3799){ref-type="fig"}). Heterogeneity may have been caused by different times of Gln supplementation or different doses, or by the type of disease. Thus, the random-effects model was utilized for the meta-analysis. Gln was found to significantly decrease intestinal permeability (WMD=−0.05, 95% CI: −0.09, −0.01; P=0.007; [Fig. 8](#f8-etm-0-0-3799){ref-type="fig"}). Publication bias is shown in [Fig. 8](#f8-etm-0-0-3799){ref-type="fig"}.

Modulation of the diamine oxidase levels was also analyzed. Four studies comprising 160 patients were included. The heterogeneity was acceptable (χ^2^=3.81, P=0.28, I^2^=21%), allowing to use the fixed effects model for meta-analysis. Gln significantly decreased the levels of diamine oxidase (WMD=−1.60, 95% CI: −1.89, −1.31; P\<0.00001; [Fig. 9](#f9-etm-0-0-3799){ref-type="fig"}). Publication bias is shown in [Fig. 10](#f10-etm-0-0-3799){ref-type="fig"}.

The effects of Gln supplementation on the levels of D(−)lactic acid were analyzed. Three studies (n=160) reported the effects after abdominal surgery. Due to the heterogeneity of these studies (χ^2^=134.29, P≤0.00001, I^2^=99%), the random-effects model was utilized. The difference between Gln-treated and control patients did not reach statistical significance (WMD=−8.14, 95% CI: −18.12, −1.84; P=0.11; [Fig. 11](#f11-etm-0-0-3799){ref-type="fig"}).

The effects of Gln on endotoxin levels were then analyzed. Five studies comprising 210 subjects were performed and the endotoxin levels reported. The studies were heterogeneous (χ^2^=983.78, P\<0.0001, I^2^=100%), prompting us to use the random effects model. The results showed that Gln significantly decreases the levels of endotoxin (WMD=−0.36, 95% CI: −0.45, −0.27; P\<0.00001; [Fig. 12](#f12-etm-0-0-3799){ref-type="fig"}).

Discussion
==========

Gln is as an important free amino acid in the human body and is used in clinical practice as a supportive supplementation. Gln improves immune function and nutritional status, and protects gastrointestinal mucosa. These effects promote patient recovery. Gln ameliorates the function of intestinal mucosal cells, lymphocytes, macrophages, and neutrophils ([@b12-etm-0-0-3799]--[@b15-etm-0-0-3799]). This amino acid is indispensible for intestinal mucosal epithelial cell metabolism as it improves intestinal mucosal repair and restoration of barrier function of the intestinal mucosa ([@b26-etm-0-0-3799],[@b27-etm-0-0-3799]). Thus, patients who do not receive Gln supplementation demonstrate increased intestinal permeability ([@b28-etm-0-0-3799]).

Our study evaluated the effects of Gln on inflammatory markers CRP, TNF-α, IL-2R, and IL-6 in patients after abdominal surgery. CRP, often used as an inflammatory and disease activity marker ([@b29-etm-0-0-3799]), is a sensitive marker of non-specific inflammatory response. TNF-α is an important inflammatory mediator in trauma, infection and stress situations. IL-2R binds to IL-2, which is an important immune regulatory cytokine ([@b30-etm-0-0-3799]). IL-6 is an inflammatory mediator closely associated with disease outcome and prognosis. The results of the present meta-analysis show that the levels of CRP, TNF-α, and IL-6 were decreased by Gln supplementation, whereas the levels of IL-2R were increased.

We evaluated the effects of Gln on the markers of intestinal mucosal permeability, as demonstrated by parameters such as lactulose/mannitol ratio, and the levels of diamine oxidase, D(−)lactic acid, and endotoxin. When the intestinal mucosal barrier function is impaired, the connection between intestinal mucosal cells is disturbed and intercellular space increases, leading to an increased lactulose/mannitol ratio ([@b31-etm-0-0-3799]). Damaged intestinal mucosal epithelial cells release diamine oxidase, which elevated the levels of this marker in blood plasma. Therefore, diamine oxidase is a reliable plasma marker for indirect assessment of the integrity of the mucosal epithelial cell layer ([@b32-etm-0-0-3799],[@b33-etm-0-0-3799]). D(−)lactic acid is the metabolite of bacterial fermentation. When intestinal mucous membrane permeability increases, higher levels of D(−)lactic acid reach the bloodstream ([@b34-etm-0-0-3799]). Thus, monitoring of D(−)lactic acid levels in blood can reflect intestinal mucosal damage and impaired permeability. Endotoxin is a virulence factor produced by gram-negative bacteria. Under normal circumstances, intact intestinal barrier prevents endotoxin from entering the blood circulation ([@b33-etm-0-0-3799]). When the intestinal barrier is damaged, endotoxin levels in peripheral blood increase. Our analyses show that the lactulose/mannitol ratio, and the levels of diamine oxidase and endotoxin were significantly lower in patients supplemented with Gln. This result indicates that Gln can decrease intestinal mucosal permeability in patients after abdominal surgery and restore the intestinal mucosal barrier function.

This meta-analysis also has certain limitations. First, this study included 21 studies, with higher proportion of studies from China and lower proportion of international studies. This constituted a possible selection bias. Second, whereas all the studies included in the meta-analysis utilized a randomized and parallel study design, they were not always blinded. Third, because of insufficient sample size, publication bias may be large. For example, since there were only three published reports on D(−)lactic acid, heterogeneity and publication bias was sizable.

In conclusion, Gln appears to effectively reduce the inflammatory response and intestinal mucosal permeability in patients after abdominal surgery.

The present study was supported by the 'Twelfth Five-Year' National Key Technology R&D Program of China (grant no. 2012BAI35B03).
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###### 

Methodological quality assessment of randomized controlled studies.

  Items                      0                                                         1                                                           2
  -------------------------- --------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------
  Randomization              Not randomized or inappropriate method of randomization   Randomized study design                                     Randomization method has been described and has been appropriate
  Double blinding            No blinding or inappropriate method of blinding           Double-blinded study                                        The method of double blinding has been described and has been appropriated
  Withdrawals and dropouts   Follow up not described                                   Description of withdrawals and dropouts has been included   

###### 

RCTs included in the meta-analysis.

                         Sample size   Mean age    Gender (M vs. F)                                                                                     
  ---------------------- ------------- ----------- --------------------- ----------------------------- -------------------------------------------- --- ------------------------
  Dong *et al* (2008)    20/20         64.2/66.5   14 vs. 6/13 vs. 7     Total gastrectomy             CRP, TNF-α                                   4     ([@b5-etm-0-0-3799])
  Li *et al* (2012)      40/40         58/57       23 vs. 17/25 vs. 15   Gastric cancer                TNF-α and IL-6                               4     ([@b6-etm-0-0-3799])
  Feng *et al* (2007)    58/58         56/56                             Gastric cancer                TNF-α                                        4     ([@b7-etm-0-0-3799])
  Lu *et al* (2011)      25/25         66.6/66.8   16 vs. 9/18 vs. 7     Gastrointestinal cancer       CRP, TNF-α, IL-6                             4     ([@b8-etm-0-0-3799])
  Richard *et al* 2014   11/11         47/45         5 vs. 6/6 vs. 5     Hepatic resection             CRP                                          4     ([@b9-etm-0-0-3799])
  Yeh *et al* (2008)     35/35         59/58       18 vs. 17/20 vs. 15   Gastrointestinal surgery      CRP                                          4   ([@b10-etm-0-0-3799])
  Xu *et al* (2011)      40/40         61.2/62.3   21 vs. 19/20 vs. 20   Gastrectomy                   TNF-α, lactulose/mannitol, diamine oxidase   3   ([@b11-etm-0-0-3799])
  Yang *et al* (1999)    7/7           43/43                             Gastrectomy                   IL-2R                                        3   ([@b12-etm-0-0-3799])
  Song *et al* (2002)    20/20         56/56                             Colorectal cancer             IL-2R                                        4   ([@b13-etm-0-0-3799])
  Quan *et al* (2010)    10/10         52/50         6 vs. 4/5 vs. 5     Abdominal surgery             IL-6, Lactulose/mannitol, diamine oxidase    4   ([@b14-etm-0-0-3799])
  Lin *et al* (2005)     23/25         67.6/66.7   14 vs. 9/14 vs. 11    Abdominal surgery             IL-6                                         4   ([@b15-etm-0-0-3799])
  Jian *et al* (1999)    30/30         54.5/55.5   31 vs. 29/35 vs. 25   Gastrointestinal surgery      Lactulose/mannitol                           4   ([@b16-etm-0-0-3799])
  Quan *et al* (2004)    10/10         48.3/48.3     7 vs. 3/6 vs. 4     Abdominal surgery             Lactulose/mannitol, diamine oxidase          4   ([@b17-etm-0-0-3799])
  Zhu *et al* (2005)     20/21         67.6/68.4   12 vs. 8/12 vs. 9     Abdominal secondary surgery   Lactulose/mannitol, endotoxin                4   ([@b18-etm-0-0-3799])
  Zhu *et al* (2000)     15/15         66.7/68.3     7 vs. 8/6 vs. 9     Gastrointestinal surgery      Lactulose/mannitol                           4   ([@b19-etm-0-0-3799])
  Zhao *et al* (2010)    20/20         61.7/62.5   12 vs. 8/14 vs. 6     Gastric cancer                  Diamine oxidase, D(−)lactic acid           3   ([@b20-etm-0-0-3799])
  Gu *et al* (2006)      36/36         61.7/62.5   28 vs. 12/20 vs. 12   Gastric cancer                D(−)lactic acid                              3   ([@b21-etm-0-0-3799])
  Niu *et al* (2011)     29/29                     15 vs. 14/17 vs. 12   Abdominal surgery             D(−)lactic acid                              3   ([@b22-etm-0-0-3799])
  Li *et al* (2006)      40/40         57.6/58.2   30 vs. 10/27 vs. 13   Cardiac carcinoma             Endotoxin                                    4   ([@b23-etm-0-0-3799])
  Yao *et al* (2002)     14/14         60.1/59.0                         Abdominal surgery             Endotoxin                                    4   ([@b24-etm-0-0-3799])
  Yao *et al* (2005)     20/20         57.4/56.1                         Gastrointestinal surgery      Endotoxin                                    4   ([@b25-etm-0-0-3799])

RCT, randomized controlled trial; TNF-α, tumor necrosis factor-α; IL, interleukin; CRP, C-reactive protein; F, female; M, male.
